Prostate Cancer Screening
Men should discuss with their physicians the risks and benefits of prostate cancer screening to make an informed decision about testing. Most men should consider regular prostate screenings beginning at age 50. Men at high risk (African Americans and men whose father, brother, or son was diagnosed with prostate cancer before age 65) should consider testing beginning at age 45. Consider screening at age 40 if more than one first-degree relative was diagnosed at an early age. Prostate screenings can include the PSA (prostate-specific antigen) blood test and DRE (digital rectal exam).
Texas Center for Proton Therapy now offers a new, FDA approved test to screen for prostate cancer – including metastatic or recurrent forms of the disease, which may be difficult to detect with a conventional CT scan, MRI, or bone scan. This new testing option, called piflufolastat F18 or PSMA PET, is the newest FDA-approved imaging agent for detecting prostate cancer via PET scan. The imaging agent helps detect and stage prostate cancer by attaching itself to prostate-specific membrane antigens, which are highly expressed in prostate cancer cells.
Prostate Cancer Treatment
Prostate cancer may be treated by different members of the cancer care team. Treatment options vary depending on how advanced the cancer is and if it has spread to other body parts. Physicians will determine the most appropriate treatment for each patient, including surveillance, surgery, radiation therapy, proton therapy, hormone therapy, chemotherapy, vaccine treatment, bone-directed treatment, immunotherapy, and cryotherapy.
Some men will have persistent or recurrent disease after their initial therapy, such as surgery and radiation. In these cases, early detection can optimize further treatment and help identify those who have the best opportunity for care.
Texas Center for Proton Therapy offers Axumin® imaging in combination with scans, such as position emission tomography (PET) imaging, for prostate cancer detection in patients with recurrent or persistent prostate cancer after initial treatment.
Dr. Andrew Lee, medical director at Texas Center for Proton Therapy, answers commonly asked questions about prostate cancer screening, diagnosis and treatment.
After serving in Vietnam, the Horton brothers found themselves both facing a prostate cancer diagnosis, but several years apart. The two men both chose proton therapy as their treatment option, but in different states. John overviews his experience at Texas Center for Proton Therapy.